Mizuho Securities analyst Difei Yang maintained a Buy rating on Revance Therapeutics (RVNC) yesterday and set a price target of $35.00. The company’s shares closed last Tuesday at $20.03.
According to TipRanks.com, Yang has 0 stars on 0-5 stars ranking scale with an average return of -8.4% and a 34.8% success rate. Yang covers the Healthcare sector, focusing on stocks such as Xeris Pharmaceuticals, Sarepta Therapeutics, and Nektar Therapeutics.
Currently, the analyst consensus on Revance Therapeutics is a Strong Buy with an average price target of $32.25, implying a 55.9% upside from current levels. In a report issued on May 4, H.C. Wainwright also maintained a Buy rating on the stock with a $24.00 price target.
See today’s analyst top recommended stocks >>
Based on Revance Therapeutics’ latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of $58K and GAAP net loss of $61.93 million. In comparison, last year the company earned revenue of $278K and had a GAAP net loss of $35.3 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Revance Therapeutics, Inc. is a clinical stage biotechnology company. It engages in the development, manufacturing, and commercialization of novel botulinum toxin products for multiple aesthetic and therapeutic applications. The firm focuses on production of daxibotulinumtoxinA, a botulinum toxin, for aesthetic and therapeutic indications, including facial wrinkles and muscle movement disorders. The company was founded by Jacob M. Waugh and L. Daniel Browne on August 10, 1999 and is headquartered in Newark, CA.
